{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:17:19Z","timestamp":1775477839953,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T00:00:00Z","timestamp":1635811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondation contre le Cancer \/ Stichting Tegen Kanker"},{"name":"Fonds de la recherche scientifique - fnrs"},{"name":"Intergroupe Francophone du My\u00e9lome"},{"DOI":"10.13039\/501100005627","name":"Universit\u00e9 de Li\u00e8ge","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005627","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CHU de Li\u00e8ge"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Antibody-based therapies targeting CD38 are currently used as single agents as well as in combination regimens for multiple myeloma, a malignant plasma cell disorder. In this study, we aimed to develop anti-CD38 single-domain antibodies (sdAbs) that can be used to trace CD38<jats:sup>+<\/jats:sup>\u2009tumour cells and subsequently used for targeted radionuclide therapy. SdAbs are derived from <jats:italic>Camelidae<\/jats:italic> heavy-chain antibodies and have emerged as promising theranostic agents due to their favourable pharmacological properties.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Four different anti-CD38 sdAbs were produced, and their binding affinities and potential competition with the monoclonal antibody daratumumab were tested using biolayer interferometry. Their binding kinetics and potential cell internalisation were further studied after radiolabelling with the diagnostic radioisotope Indium-111. The resulting radiotracers were evaluated in vivo for their tumour-targeting potential and biodistribution through single-photon emission computed tomography (SPECT\/CT) imaging and serial dissections. Finally, therapeutic efficacy of a lead anti-CD38 sdAb, radiolabelled with the therapeutic radioisotope Lutetium-177, was evaluated in a CD38<jats:sup>+<\/jats:sup>\u2009MM xenograft model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results\u00a0<\/jats:title>\n                <jats:p>We retained anti-CD38 sdAb #2F8 as lead based on its excellent affinity and superior stability, the absence of competition with daratumumab and the lack of receptor-mediated internalisation. When intravenously administered to tumour-xenografted mice, radiolabelled sdAb #2F8 revealed specific and sustained tumour retention with low accumulation in other tissues, except kidneys, resulting in high tumour-to-normal tissue ratios. In a therapeutic setting, myeloma-bearing mice received three consecutive intravenous administrations of a high (18.5\u00a0MBq) or a low radioactive dose (9.3\u00a0MBq) of <jats:sup>177<\/jats:sup>Lu-DTPA-2F8 or an equal volume of vehicle\u00a0solution. A dose-dependent tumour regression was observed, which translated into a prolonged median survival from 43\u00a0days for vehicle-treated mice, to 62\u00a0days (<jats:italic>p<\/jats:italic>\u2009=\u20090.027) in mice receiving the low and 65\u00a0days in mice receiving the high (<jats:italic>p<\/jats:italic>\u2009=\u20090.0007) radioactive dose regimen, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results highlight the theranostic potential of radiolabelled anti-CD38 sdAbs for the monitoring and treatment of multiple myeloma.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-021-01171-6","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T10:04:57Z","timestamp":1635847497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma"],"prefix":"10.1186","volume":"14","author":[{"given":"Elodie","family":"Duray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Beguin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Devoogdt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"Krasniqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoline","family":"Lauwers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"D\u2019Huyvetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-1195","authenticated-orcid":false,"given":"Jo","family":"Caers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,2]]},"reference":[{"issue":"10","key":"1171_CR1","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1021\/bc200151q","volume":"22","author":"SS Kelkar","year":"2011","unstructured":"Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011;22(10):1879\u2013903.","journal-title":"Bioconjug Chem"},{"key":"1171_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, Van Duin M, Sonneveld P, Mateos MV, et al. Multiple myeloma. Nat Rev Dis Prim. 2017;3:1\u201320. https:\/\/doi.org\/10.1038\/nrdp.2017.46.","journal-title":"Nat Rev Dis Prim."},{"issue":"1","key":"1171_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"NWCJ van de Donk","year":"2018","unstructured":"van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13\u201329.","journal-title":"Blood"},{"issue":"2","key":"1171_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2967\/jnumed.117.196063","volume":"59","author":"A Ghai","year":"2018","unstructured":"Ghai A, Maji D, Cho N, Chanswangphuwana C, Rettig M, Shen D, et al. Preclinical development of CD38-Targeted [(89)Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. J Nucl Med. 2018;59(2):216\u201322.","journal-title":"J Nucl Med"},{"key":"1171_CR5","doi-asserted-by":"publisher","first-page":"27055","DOI":"10.1038\/srep27055","volume":"6","author":"T Li","year":"2016","unstructured":"Li T, Qi S, Unger M, Hou YN, Deng QW, Liu J, et al. Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep. 2016;6:27055.","journal-title":"Sci Rep"},{"issue":"1","key":"1171_CR6","doi-asserted-by":"publisher","first-page":"14289","DOI":"10.1038\/s41598-017-14112-6","volume":"7","author":"W Fumey","year":"2017","unstructured":"Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schutze K, Unger M, et al. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo. Sci Rep. 2017;7(1):14289.","journal-title":"Sci Rep"},{"issue":"6","key":"1171_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1182\/blood-2017-09-807610","volume":"131","author":"DJ Green","year":"2018","unstructured":"Green DJ, O\u2019Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, et al. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood. 2018 ;131(6):611\u201320.","journal-title":"Blood"},{"issue":"12","key":"1171_CR8","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1517\/17425247.2014.941803","volume":"11","author":"M D\u2019Huyvetter","year":"2014","unstructured":"D\u2019Huyvetter M, Xavier C, Caveliers V, Lahoutte T, Muyldermans S, Devoogdt N. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opin Drug Deliv. 2014;11(12):1939\u201354.","journal-title":"Expert Opin Drug Deliv"},{"key":"1171_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.biochi.2015.01.012","volume":"111","author":"C Pain","year":"2015","unstructured":"Pain C, Dumont J, Dumoulin M. Camelid single-domain antibody fragments: Uses and prospects to investigate protein misfolding and aggregation, and to treat diseases associated with these phenomena. Biochimie. 2015;111:82\u2013106.","journal-title":"Biochimie"},{"issue":"3","key":"1171_CR10","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1110\/ps.34602","volume":"11","author":"M Dumoulin","year":"2002","unstructured":"Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LGJ, et al. Single-domain antibody fragments with high conformational stability. Protein Sci. 2002;11(3):500\u201315.","journal-title":"Protein Sci"},{"issue":"7","key":"1171_CR11","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1111\/febs.15515","volume":"288","author":"S Muyldermans","year":"2021","unstructured":"Muyldermans S. A guide to: generation and design of nanobodies. FEBS J. 2021;288(7):2084\u2013102.","journal-title":"FEBS J"},{"key":"1171_CR12","doi-asserted-by":"crossref","unstructured":"Ackaert C, Smiejkowska N, Xavier C, Sterckx YGJ, Denies S, Stijlemans B, et al. Immunogenicity Risk Profile of Nanobodies. Front Immunol. 2021;12(March).","DOI":"10.3389\/fimmu.2021.632687"},{"issue":"10","key":"1171_CR13","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1128\/AAC.45.10.2807-2812.2001","volume":"45","author":"KE Conrath","year":"2001","unstructured":"Conrath KE, Lauwereys M, Galleni M, Matagne A, Fr\u00e8re JM, Kinne J, et al. \u03b2-Lactamase inhibitors derived from single-domain antibody fragments elicited in the Camelidae. Antimicrob Agents Chemother. 2001;45(10):2807\u201312.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"1171_CR14","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1021\/acs.molpharmaceut.8b00584","volume":"15","author":"N An","year":"2018","unstructured":"An N, Hou YN, Zhang QX, Li T, Zhang QL, Fang C, et al. Anti-multiple myeloma activity of nanobody-based anti-CD38 chimeric antigen receptor T cells. Mol Pharm. 2018;15(10):4577\u201388.","journal-title":"Mol Pharm"},{"key":"1171_CR15","doi-asserted-by":"crossref","unstructured":"Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science (80- ). 1988;240(4855):1038 LP \u2013 1041.","DOI":"10.1126\/science.3285470"},{"issue":"1","key":"1171_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jmb.2008.11.046","volume":"386","author":"H El Hajjaji","year":"2009","unstructured":"El Hajjaji H, Dumoulin M, Matagne A, Colau D, Roos G, Messens J, et al. The zinc center influences the redox and thermodynamic properties of Escherichia coli thioredoxin 2. J Mol Biol. 2009;386(1):60\u201371.","journal-title":"J Mol Biol"},{"issue":"4","key":"1171_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/10428194.2018.1508663","volume":"60","author":"M-S Dheur","year":"2019","unstructured":"Dheur M-S, Poirel HA, Ameye G, Tilman G, Saussoy P, Defour J-P, et al. Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies. Leuk Lymphoma. 2019;60(4):1043\u201352.","journal-title":"Leuk Lymphoma"},{"key":"1171_CR18","doi-asserted-by":"crossref","unstructured":"Lejeune M, Duray E, Peipp M, Clemenceau B, Baron F, Beguin Y, et al. Balancing the CD38 expression on effector and target cells in daratumumab-mediated NK Cell ADCC in the multiple myeloma context. Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13123072"},{"key":"1171_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/978-1-61779-968-6_30","volume":"911","author":"C Xavier","year":"2012","unstructured":"Xavier C, Devoogdt N, Hernot S, Vaneycken I, D\u2019Huyvetter M, De Vos J, et al. Site-specific labeling of his-tagged Nanobodies with (9)(9)mTc: a practical guide. Methods Mol Biol. 2012;911:485\u201390.","journal-title":"Methods Mol Biol"},{"issue":"7","key":"1171_CR20","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1096\/fj.10-180331","volume":"25","author":"I Vaneycken","year":"2011","unstructured":"Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011;25(7):2433\u201346.","journal-title":"FASEB J"},{"issue":"3","key":"1171_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1162\/153535003322556877","volume":"2","author":"AM Loening","year":"2003","unstructured":"Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2(3):131\u20137.","journal-title":"Mol Imaging"},{"issue":"7","key":"1171_CR22","doi-asserted-by":"publisher","first-page":"708","DOI":"10.7150\/thno.8156","volume":"4","author":"M D\u2019Huyvetter","year":"2014","unstructured":"D\u2019Huyvetter M, Vincke C, Xavier C, Aerts A, Impens N, Baatout S, et al. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody. Theranostics. 2014;4(7):708\u201320.","journal-title":"Theranostics"},{"issue":"12","key":"1171_CR23","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1158\/1535-7163.MCT-17-0554","volume":"16","author":"A Krasniqi","year":"2017","unstructured":"Krasniqi A, D\u2019Huyvetter M, Xavier C, Van der Jeught K, Muyldermans S, Van Der Heyden J, et al. Theranostic radiolabeled Anti-CD20 sdAb for targeted radionuclide therapy of non-hodgkin lymphoma. Mol Cancer Ther. 2017;16(12):2828\u201339.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1171_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","volume":"30","author":"EJ Rolleman","year":"2003","unstructured":"Rolleman EJ, Valkema R, de Jong M, Kooij PPM, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30(1):9\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1171_CR25","doi-asserted-by":"crossref","unstructured":"Wang C, Chen Y, Hou YN, Liu Q, Zhang D, Zhao H, et al. ImmunoPET imaging of multiple myeloma with [(68)Ga]Ga-NOTA-Nb1053. Eur J Nucl Med Mol Imaging. 2021 Feb;","DOI":"10.21203\/rs.3.rs-188294\/v1"},{"issue":"1","key":"1171_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-14112-6","volume":"7","author":"W Fumey","year":"2017","unstructured":"Fumey W, Koenigsdorf J, Kunick V, Menzel S, Sch\u00fctze K, Unger M, et al. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+tumors in mouse models in vivo. Sci Rep. 2017;7(1):1\u201313.","journal-title":"Sci Rep"},{"key":"1171_CR27","doi-asserted-by":"crossref","unstructured":"Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7(10):e1486948.","DOI":"10.1080\/2162402X.2018.1486948"},{"issue":"7","key":"1171_CR28","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959\u201370.","journal-title":"Blood"},{"issue":"5","key":"1171_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF00448541","volume":"9","author":"D Goodwin","year":"1984","unstructured":"Goodwin D, Meares C, Diamanti C, McCall M, Lai C, Torti F, et al. Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins. Eur J Nucl Med. 1984;9(5):209\u201315.","journal-title":"Eur J Nucl Med"},{"issue":"3","key":"1171_CR30","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1148\/radiol.2020192621","volume":"295","author":"GA Ulaner","year":"2020","unstructured":"Ulaner GA, Sobol NB, O\u2019Donoghue JA, Kirov AS, Riedl CC, Min R, et al. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. Radiology. 2020;295(3):606\u201315.","journal-title":"Radiology"},{"issue":"20","key":"1171_CR31","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1182\/bloodadvances.2020002603","volume":"4","author":"A Krishnan","year":"2020","unstructured":"Krishnan A, Adhikarla V, Poku EK, Palmer J, Chaudhry A, Biglang-Awa VE, et al. Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. Blood Adv. 2020;4(20):5194\u2013202.","journal-title":"Blood Adv"},{"issue":"6","key":"1171_CR32","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2967\/jnumed.117.199901","volume":"59","author":"A Krasniqi","year":"2018","unstructured":"Krasniqi A, D\u2019Huyvetter M, Devoogdt N, Frejd FY, Sorensen J, Orlova A, et al. Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. J Nucl Med. 2018;59(6):885\u201391.","journal-title":"J Nucl Med"},{"issue":"1","key":"1171_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.115.162024","volume":"57","author":"M Keyaerts","year":"2016","unstructured":"Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase i study of 68Ga-HER2-Nanobody for PET\/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57(1):27\u201333.","journal-title":"J Nucl Med"},{"key":"1171_CR34","doi-asserted-by":"crossref","unstructured":"D\u2019Huyvetter M, De Vos J, Caveliers V, Vaneycken I, Heemskerk J, Duhoux FP, et al. Phase I trial of (131)I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients. J Nucl Med. 2020 Dec;","DOI":"10.2967\/jnumed.120.255679"},{"issue":"2","key":"1171_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s002590050216","volume":"25","author":"TM Behr","year":"1998","unstructured":"Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25(2):201\u201312.","journal-title":"Eur J Nucl Med"},{"issue":"3","key":"1171_CR36","first-page":"432","volume":"47","author":"E Vegt","year":"2006","unstructured":"Vegt E, Wetzels JFM, Russel FGM, Masereeuw R, Boerman OC, van Eerd JE, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med. 2006;47(3):432\u20136.","journal-title":"J Nucl Med"},{"issue":"13","key":"1171_CR37","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(13):2124\u201330.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4","key":"1171_CR38","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1158\/0008-5472.CAN-13-1589","volume":"74","author":"DJ Green","year":"2014","unstructured":"Green DJ, Orgun NN, Jones JC, Hylarides MD, Pagel JM, Hamlin DK, et al. A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer Res. 2014;74(4):1179\u201389.","journal-title":"Cancer Res"},{"issue":"7","key":"1171_CR39","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2967\/jnumed.119.239491","volume":"61","author":"I Quelven","year":"2020","unstructured":"Quelven I, Monteil J, Sage M, Saidi A, Mounier J, Bayout A, et al. (212)Pb \u03b1-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study. J Nucl Med. 2020;61(7):1058\u201365.","journal-title":"J Nucl Med"},{"issue":"9","key":"1171_CR40","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2967\/jnumed.112.111997","volume":"54","author":"M Cherel","year":"2013","unstructured":"Cherel M, Gouard S, Gaschet J, Sai-Maurel C, Bruchertseifer F, Morgenstern A, et al. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med. 2013;54(9):1597\u2013604.","journal-title":"J Nucl Med"},{"issue":"8","key":"1171_CR41","doi-asserted-by":"publisher","first-page":"1607673","DOI":"10.1080\/2162402X.2019.1607673","volume":"8","author":"W Dawicki","year":"2019","unstructured":"Dawicki W, Allen KJH, Jiao R, Malo ME, Helal M, Berger MS, et al. Daratumumab-(225)Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors. Oncoimmunology. 2019;8(8):1607673.","journal-title":"Oncoimmunology"},{"issue":"6","key":"1171_CR42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.120.251983","volume":"62","author":"M Minnix","year":"2021","unstructured":"Minnix M, Adhikarla V, Caserta E, Poku E, Rockne R, Shively JE, et al. Comparison of CD38 targeted alpha- vs betaradionuclide therapy of disseminated multiple myeloma in an animal model. J Nucl Med. 2021;62(6):795\u2013801.","journal-title":"J Nucl Med."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01171-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T10:17:32Z","timestamp":1635848252000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01171-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,2]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01171-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,2]]},"assertion":[{"value":"30 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mice experiments were approved by the Ethical Committees for Animal Experiments of the University of Li\u00e8ge and of Vrije Universiteit Brussel.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.D. and N.D. are, respectively, employee and consultant of Precirix NV and hold ownership interest (including patents) in sdAb radiodiagnostics and radiotherapeutics. N.D. is co-founder of Abscint and together with M.D. co-founder of Precirix NV.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}